Loading...
0

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

LI_15121
Pages: 252
Feb 2019 | 102120 Views
 
Author(s) : Sanjivan Gill & Onkar Sumant
Tables: 153
Charts: 59
 

Oncology Drugs Market Overview:

The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Cancer is a disease, which involves the abnormal growth of cells that results in the formation of a tumor. However benign tumors are not cancers. The abnormal tumor cells have the tendency to spread to other local tissues and may also spread to different parts of body through blood and lymphatic system. Different types of cancers such as lung cancer, colorectal, breast cancer, and others are predominant among the populace. Treatment of cancer depends upon the stages of the disease progression. Chemotherapy is majorly used in the earlier stages whereas other therapy options such as targeted therapy drugs, immunological therapy drugs are used in late stage.

Cancer has a widespread prevalence worldwide, which has led to rise in demand for cancer drugs. The key factors that are responsible for the growth of the oncology/cancer drugs market are surge in cancer research, rise in geriatric population worldwide, and increase in number of collaborations between pharmaceutical companies. In addition, rise in healthcare expenditure worldwide is expected to boost the market expansion.

Moreover, high market growth potential in developing nations, rise in number of pipeline products, and upsurge in demand for personalized medicines are expected to create new opportunities for the market players during the forecast period. However, adverse effects associated with the use of cancer drugs and high costs related with cancer drug development are the major factors that impede the growth of the market.

Get more information on this report: Request Sample Pages

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. On the basis of drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy, and others. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment review

Get more information on this report: Request Sample Pages

According to drug class type, the targeted therapy segment occupied the largest oncology/cancer drugs market share in 2017. This is due to the ability of targeted therapies to kill only malignant cells, higher efficacy and higher survival rates associated with their use. The immunotherapy segment is expected to show fastest growth during the forecast period, registering a CAGR of 10.4%. This is attributed to surge in incidence of cancer worldwide and high unmet medical needs in some countries. Immunotherapy drugs are widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body which makes them less toxic as compared to other modes of cancer therapies. Moreover, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types serves as a key factor for the growth of the oncology/cancer drugs market.

According to indication, the prostate cancer segment occupied the largest oncology/cancer drugs market share in 2017. This is due to presence of huge geriatric population. The lung cancer segment is expected to show fastest growth during the forecast period. This is due to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.

Get more information on this report: Request Sample Pages

Snapshot of Asia-Pacific oncology/cancer drugs market

Asia-Pacific oncology/cancer drugs market possesses high growth potential, owing to rise in cancer awareness across the region and increase in R&D investment. Furthermore, this region presents notable opportunities for the venture capitalists and investors, as the developed markets are comparatively saturated. Moreover, increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers are some other factors, which contribute toward the growth of the oncology/cancer drugs market in this region. In addition, widespread prevalence of certain cancers, such stomach cancer, and presence of huge geriatric population in countries such as Japan drive the market growth in this region.

Get more information on this report: Request Sample Pages

The report provides an extensive competitive analysis and profiles of the key market players such as AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, f. Hoffmann-La Roche ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, and Pfizer Inc..
The other players in the value chain include Sanofi, Amgen Inc. Bayer AG, and Exelixis, Inc.

Key Benefits for Oncology Drugs Market:

  • This report entails a detailed quantitative analysis along with current oncology/cancer drugs market trends of the oncology/cancer drugs market from 2017 to 2025 to identify the prevailing opportunities along with strategic assessment of the global oncology/cancer drugs market.
  • The oncology/cancer drugs market forecast is studied from 2018 to 2025.
  • Oncology/cancer drugs market size and estimations are based on a comprehensive analysis of key developments in the oncology/cancer drugs industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global oncology/cancer drugs market.

Oncology Drugs Key Market Segments:

By Drug Class Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017

3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Patent analysis (2015-2018)

3.6.1. Patent analysis, world
3.6.2. Patent analysis, by year

3.7. Market dynamics

3.7.1. Drivers

3.7.1.1. Rise in incidence of cancer across the globe
3.7.1.2. Surge in global geriatric population
3.7.1.3. Increase in government expenditures on healthcare

3.7.2. Restraints

3.7.2.1. Adverse effects associated with the use of cancer drugs

3.7.3. Opportunities

3.7.3.1. Untapped emerging economies
3.7.3.2. Increase in number of pipeline drugs

3.7.4. Impact Analyses

CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Chemotherapy

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Targeted Therapy

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Immunotherapy (Biologic Therapy)

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Hormonal Therapy

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Lung Cancer

5.2.1. Market size and forecast, by region
5.2.2. Market share analysis, by country

5.3. Stomach Cancer

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Colorectal Cancer

5.4.1. Market size and forecast, by region
5.4.2. Market share analysis, by country

5.5. Breast Cancer

5.5.1. Market size and forecast, by region
5.5.2. Market share analysis, by country

5.6. Prostate Cancer

5.6.1. Market size and forecast, by region
5.6.2. Market share analysis, by country

5.7. Liver Cancer

5.7.1. Market size and forecast, by region
5.7.2. Market share analysis, by country

5.8. Esophagus Cancer

5.8.1. Market size and forecast, by region
5.8.2. Market share analysis, by country

5.9. Cervical Cancer

5.9.1. Market size and forecast, by region
5.9.2. Market share analysis, by country

5.10. Kidney Cancer

5.10.1. Market size and forecast, by region
5.10.2. Market share analysis, by country

5.11. Bladder Cancer

5.11.1. Market size and forecast, by region
5.11.2. Market share analysis, by country

5.12. Other Cancers

5.12.1. Market size and forecast, by region
5.12.2. Market share analysis, by country

CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type
6.2.2.1.2. U.S. oncology/cancer drugs market, by indication

6.2.2.2. Canada

6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type
6.2.2.2.2. Canada oncology/cancer drugs market, by indication

6.2.2.3. Mexico

6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type
6.2.2.3.2. Mexico oncology/cancer drugs market, by indication

6.2.3. Market size and forecast, by drug class type
6.2.4. Market size and forecast, by indication

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type
6.3.2.1.2. Germany oncology/cancer drugs market, by indication

6.3.2.2. France

6.3.2.2.1. France oncology/cancer drugs market, by drug class type
6.3.2.2.2. France oncology/cancer drugs market, by indication

6.3.2.3. UK

6.3.2.3.1. UK oncology/cancer drugs market, by drug class type
6.3.2.3.2. UK oncology/cancer drugs market, by indication

6.3.2.4. Italy

6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type
6.3.2.4.2. Italy oncology/cancer drugs market, by indication

6.3.2.5. Spain

6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type
6.3.2.5.2. Spain oncology/cancer drugs market, by indication

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type
6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication

6.3.3. Market size and forecast, by drug class type
6.3.4. Market size and forecast, by indication

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type
6.4.2.1.2. Japan oncology/cancer drugs market, by indication

6.4.2.2. China

6.4.2.2.1. China oncology/cancer drugs market, by drug class type
6.4.2.2.2. China oncology/cancer drugs market, by indication

6.4.2.3. Australia

6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type
6.4.2.3.2. Australia oncology/cancer drugs market, by indication

6.4.2.4. India

6.4.2.4.1. India oncology/cancer drugs market, by drug class type
6.4.2.4.2. India oncology/cancer drugs market, by indication

6.4.2.5. South Korea

6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type
6.4.2.5.2. South Korea oncology/cancer drugs market, by indication

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication

6.4.3. Market size and forecast, by drug class type
6.4.4. Market size and forecast, by indication

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type
6.5.2.1.2. Brazil oncology/cancer drugs market, by indication

6.5.2.2. Saudi Arabia

6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type
6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication

6.5.2.3. South Africa

6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type
6.5.2.3.2. South Africa oncology/cancer drugs market, by indication

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type
6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication

6.5.3. Market size and forecast, by drug class type
6.5.4. Market size and forecast, by indication

CHAPTER 7: COMPANY PROFILES

7.1. AbbVie Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. Astellas Pharma Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance

7.3. AstraZeneca PLC

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. Bristol-Myers Squibb Company

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. Celgene Corporation

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product type Portfolio
7.5.5. Business performance

7.6. F. HOFFMANN-LA ROCHE LTD.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance

7.8. Merck & Co., Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Novartis AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance

7.10. Pfizer Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
TABLE 02. CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 20162023 ($MILLION)
TABLE 03. CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 20172025 ($MILLION)
TABLE 04. CANCER DRUGS FOR IMMUNOTHERAPY, BY REGION, 20172025 ($MILLION)
TABLE 05. CANCER DRUGS FOR HORMONAL THERAPY, BY REGION, 20172025 ($MILLION)
TABLE 06. GLOBAL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
TABLE 07. ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 20172025 ($MILLION)
TABLE 08. ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 20172025 ($MILLION)
TABLE 09. ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 20172025 ($MILLION)
TABLE 10. ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 20172025 ($MILLION)
TABLE 11. CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 20172025 ($MILLION)
TABLE 12. ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 20172025 ($MILLION)
TABLE 13. ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 20172025 ($MILLION)
TABLE 14. ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 20172025 ($MILLION)
TABLE 15. ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 20172025 ($MILLION)
TABLE 16. ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 20172025 ($MILLION)
TABLE 17. ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 20172025 ($MILLION)
TABLE 18. ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 20172025 ($MILLION)
TABLE 19. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 20. U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 21. U.S. CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 22. CANADA CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 23. CANADA CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 24. MEXICO CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 25. MEXICO CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 26. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
TABLE 27. NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
TABLE 28. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 29. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 30. GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 31. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 32. FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 33. UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 34. UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 35. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 36. ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 37. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 38. SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 39. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 40. REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 41. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
TABLE 42. EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
TABLE 43. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 44. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 45. JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 46. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 47. CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 48. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 49. AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 50. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 51. INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 52. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 53. SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 54. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 55. REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 56. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
TABLE 57. ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
TABLE 58. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 59. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 60. BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 61. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 62. SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 63. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 64. SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 65. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2017-2025
TABLE 66. REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2017-2025
TABLE 67. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 20172025 ($MILLION)
TABLE 68. LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 20172025 ($MILLION)
TABLE 69. ABBVIE: COMPANY SNAPSHOT
TABLE 70. ABBVIE: OPERATING SEGMENTS
TABLE 71. ABBOTT: PRODUCT PORTFOLIO
TABLE 72. ASTELLAS: COMPANY SNAPSHOT
TABLE 73. ASTELLAS: PRODUCTS AND SERVICES
TABLE 74. ASTELLAS: PRODUCT PORTFOLIO
TABLE 75. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 76. ASTRAZENECA: OPERATING SEGMENTS
TABLE 77. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 78. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 79. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 80. CELGENE: COMPANY SNAPSHOT
TABLE 81. CELGENE: OPERATING SEGMENTS
TABLE 82. CELGENE : PRODUCT TYPE PORTFOLIO
TABLE 83. ROCHE: COMPANY SNAPSHOT
TABLE 84. ROCHE: OPERATING SEGMENTS
TABLE 85. ROCHE: PRODUCT TYPE PORTFOLIO
TABLE 86. J&J: COMPANY SNAPSHOT
TABLE 87. J&J: OPERATING SEGMENTS
TABLE 88. J&J: PRODUCT TYPE PORTFOLIO
TABLE 89. MERCK: COMPANY SNAPSHOT
TABLE 90. MERCK: OPERATING SEGMENTS
TABLE 91. MERCK: PRODUCT PORTFOLIO
TABLE 92. NOVARTIS: COMPANY SNAPSHOT
TABLE 93. NOVARTIS: OPERATING SEGMENTS
TABLE 94. NOVARTIS: PRODUCT PORTFOLIO
TABLE 95. PFIZER: COMPANY SNAPSHOT
TABLE 96. PFIZER: OPERATING SEGMENTS
TABLE 97. PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, 2015-2018
FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2015-2018
FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2015-2018
FIGURE 06. TOP PLAYER POSITIONING, 2017
FIGURE 07. MODERATE BARGANING POWER OF BUYERS
FIGURE 08. HIGH BARGANING POWER OF SUPPLIERS
FIGURE 09. MODERATE THREAT OF SUBSTITUTION
FIGURE 10. MODERATE THREAT OF NEW ENTRANTS
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. PATENTS REGISTERED/APPROVED IN THE WORLD, 2015-2018
FIGURE 13. PATENTS ANALYSIS BY YEAR, 2015 THROUGH 2018
FIGURE 14. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 15. IMPACT ANALYSES, ONCOLOGY/CANCER DRUGS MARKET
FIGURE 16. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2017 & 2025
FIGURE 17. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2017 & 2025
FIGURE 18. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR IMMUNOTHERAPY, BY COUNTRY, 2017 & 2025
FIGURE 19. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR HORMONAL THERAPY, BY COUNTRY, 2017 & 2025
FIGURE 20. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2017 & 2025
FIGURE 21. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2017 & 2025
FIGURE 22. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017 & 2025
FIGURE 23. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2017 & 2025
FIGURE 24. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017 & 2025
FIGURE 25. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2017 & 2025
FIGURE 26. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2017 & 2025
FIGURE 27. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2017 & 2025
FIGURE 28. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2017 & 2025
FIGURE 29. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2017 & 2025
FIGURE 30. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017 & 2025
FIGURE 31. EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017
FIGURE 32. ABBVIE: NET SALES, 20152017 ($MILLION)
FIGURE 33. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 35. ASTELLAS: SALES, 20152017 ($MILLION)
FIGURE 36. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)
FIGURE 37. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 38. ASTRAZENECA: REVENUE, 20152017 ($MILLION)
FIGURE 39. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 40. REVENUE, 20152017 ($MILLION)
FIGURE 41. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 42. CELGENE: REVENUE, 20152017 ($MILLION)
FIGURE 43. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. CELGENE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 45. ROCHE: NET SALES, 20152017 ($MILLION)
FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 47. ROCHE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 48. J&J: REVENUE, 20152017 ($MILLION)
FIGURE 49. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 50. J&J: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 51. MERCK: NET SALES, 20152017 ($MILLION)
FIGURE 52. MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 53. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 54. NET SALES, 20152017 ($MILLION)
FIGURE 55. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 56. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 57. PFIZER: REVENUE, 20152017 ($MILLION)
FIGURE 58. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 59. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 
 

Cancer is a term coined for large group of diseases representing an abnormal growth of cells, which have the tendency to proliferate in an uncontrolled manner. Cancer is mostly named after the organ in which it initiates. Therefore, different types of cancers such as lung cancer, breast cancer, colorectal, prostate cancer, and others are prevalent among the populace. The treatment of cancer is based on the stages of progression of cancer. Various types of drugs are employed for the management of cancer such as chemotherapy, immunotherapy and others. The key factor responsible for the growth of cancer drugs market is increase in prevalence of cancer in both developed and developing economies. Furthermore, the global cancer drugs market growth is propelled by surge in geriatric population, increase in collaboration between pharmaceutical companies for development of novel cancer drugs, and rise in awareness associated with early detection of cancer among populace.

North America accounted for the highest market share in 2017, due to availability of cancer drugs, increased cancer awareness, and heavy expenditure by the government on healthcare, followed by Europe and Asia-Pacific. In addition, pharmaceutical companies have focused on expanding their presence in emerging economies, which is anticipated to drive the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
Oncology/Cancer Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Oncology/Cancer Drugs Market"
Purchase Enquiry